AVRO Stock Summary and Trading Ideas (Avrobio | NASDAQ:AVRO)

Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Avrobio trades on the NASDAQ stock market under the symbol AVRO.

As of April 17, 2024, AVRO stock price declined to $1.22 with 203,199 million shares trading.

AVRO has a beta of 1.19, meaning it tends to be more sensitive to market movements. AVRO has a correlation of 0.03 to the broad based SPY ETF.

AVRO has a market cap of $54.73 million. This is considered a Micro Cap stock.

In the last 3 years, AVRO stock traded as high as $12.01 and as low as $.56.

The top ETF exchange traded funds that AVRO belongs to (by Net Assets): VTI, VXF.

AVRO has outperformed the market in the last year with a return of +29.4%, while the SPY ETF gained +23.0%. However, in the most recent history, AVRO shares have underperformed the stock market with its stock returning -9.0% in the last 3 month period and -4.7% for the last 2 week period, while SPY has returned +5.7% and -3.5%, respectively.

AVRO support price is $1.22 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVRO stock will trade within this expected range on the day.